Aripiprazole Tablet
Product Images NDC 13668-219

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 13668-219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Containerlabel 10

Label for Aripiprazole Tablets, USP 10 mg, oral tablets. The label states a count of 30 tablets and includes the NDC 13668-218-30. It notes storage instructions to keep at 20° to 25°C with permitted excursions. Manufactured by Torrent Pharmaceuticals Limited. The label includes pharmacist dispensing instructions and a barcode.*

FDA Label Image

Image Containerlabel 15

Label for aripiprazole tablets USP, 15 mg strength, oral dosage form. The package contains 30 tablets. Label shows storage instructions, bar code, NDC 13668-219-30, and states 'Rx only.' Manufactured by Torrent Pharmaceuticals Limited. Includes pharmacist dispensing instructions and child-resistant closure information.*

FDA Label Image

Image Containerlabel 2

Label for aripiprazole Tablets USP 2 mg oral tablets, packaged as 30 tablets. The label includes storage instructions, dosage guidance to see prescribing information, and pharmacist dispensing instructions. Manufactured by Torrent Pharmaceuticals Limited. The NDC is 13668-216-30.*

FDA Label Image

Image Containerlabel 20

Packaging label for aripiprazole tablets, USP 20 mg, oral dosage form. The label indicates 30 tablets per container, with storage instructions and a note to dispense with a Medication Guide. Manufactured by Torrent Pharmaceuticals Limited and labeled for Rx only use.*

FDA Label Image

Image Containerlabel 30

Label for Aripiprazole Tablets, USP 30 mg strength, oral tablet form. The label states packaging of 30 tablets with NDC 13668-221-30. It includes storage instructions to keep between 20° to 25°C, dispensation instructions for a tight container with child-resistant closure, and notes the product is manufactured by Torrent Pharmaceuticals Limited. The label also indicates the product is Rx only.*

FDA Label Image

Image Containerlabel 5

Label for Aripiprazole Tablets USP 5 mg, oral tablets packaged as 30 tablets per bottle. The label includes storage instructions, dosage form, strength, NDC 13668-217-30, and manufacturer information for Torrent Pharmaceuticals Limited. It also indicates the product is prescription only (Rx only).*

FDA Label Image

Image Fig1 Effectofotherdrug Arip

A forest plot chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' showing fold change and 90% confidence intervals for aripiprazole AUC and Cmax with various interacting drugs. Categories include CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis shows change relative to reference (without interacting drug) from 0.5 to 3.0.*

FDA Label Image

Image Fig2 Effectofotherdrug Dehydroarip

A figure depicting the effects of various drugs on the pharmacokinetics of dehydro-aripiprazole. The chart presents fold change and 90% confidence intervals in AUC and Cmax values for inhibitors (ketoconazole, quinidine), inducer (carbamazepine), gastric acid blocker (famotidine), and other drugs (valproate, lithium, lorazepam) relative to a reference without interacting drugs.*

FDA Label Image

Image Fig3 Effectofarip Otherdrug

A pharmacokinetic chart illustrating the effects of aripiprazole on various drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The chart plots fold change and 90% confidence intervals in pharmacokinetic parameters such as AUC and Cmax relative to reference values without aripiprazole interaction.*

FDA Label Image

Image Fig4 Effectofintrinsicfactor Arip

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing a horizontal forest plot comparing various intrinsic factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment against aripiprazole fold change with 90% confidence intervals for AUC and Cmax parameters, indicating changes relative to reference values.*

FDA Label Image

Image Fig5 Effectofintrinsicfactor Dehydroarip

A pharmacokinetic chart titled 'Effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics' showing fold change and 90% confidence intervals for the pharmacokinetic parameters AUC and Cmax. Variables compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with data plotted as change relative to reference values.*

FDA Label Image

Image Fig6 Schizophreniastudy 5

Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse over days from randomization in a schizophrenia study. The graph compares relapse proportions between patients treated with aripiprazole and a placebo, with the number of subjects at risk indicated below the x-axis.*

FDA Label Image

Image Fig7 Bipolarstudy 7

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse in a bipolar study (Study 7) comparing aripiprazole and placebo groups. The graph plots the proportion with relapse over days from randomization, with aripiprazole represented by a solid blue line and placebo by a dashed red line. A table below shows the number of subjects at risk over time for each group.*

FDA Label Image

Image Fig8 Bipolarstudy 8

Kaplan-Meier plot showing the cumulative proportion of patients with relapse to any mood event over days from randomization in a bipolar study. The chart compares relapse rates between two groups: one treated with Abilify (aripiprazole) and a placebo group. The y-axis represents the proportion with relapse, and the x-axis shows days from randomization. The graph includes numbers of subjects at risk for both groups across various time points.*

FDA Label Image

Image Fig9 Tourettesdisorderstudy1

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette’s Disorder Study 1)' showing changes in YGTSS total tic scores over 8 weeks of treatment. Three lines represent ARIP-LOW, ARIP-HIGH, and Placebo groups, with the ARIP-HIGH group showing the greatest decrease in tic scores over time, followed by ARIP-LOW, and Placebo showing the least change.*

FDA Label Image

Image Logo Medguide

FDA Label Image

Image Logo Pi

FDA Label Image

Image Structure

Chemical structure of aripiprazole, showing its molecular framework with chlorine atoms, nitrogen-containing rings, and other functional groups linked in the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.